Clinical and genetic analysis of essential hypertension with mitochondrial tRNAMet 4435A>G and YARS2 mutation
OBJECTIVES: To investigate the role of m.4435A>G and YARS2 c.572G>T (p.G191V) mutations in the development of essential hypertension.
METHODS: A hypertensive patient with m.4435A>G and YARS2 p.G191V mutations was identified from previously collected mitochondrial genome and exon sequencing data. Clinical data were collected, and a molecular genetic study was conducted in the proband and his family members. Peripheral venous blood was collected, and immortalized lymphocyte lines constructed. The mitochondrial transfer RNA (tRNA), mitochondrial protein, adenosine triphosphate (ATP), mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) in the constructed lymphocyte cell lines were measured.
RESULTS: Mitochondrial genome sequencing showed that all maternal members carried a highly conserved m.4435A>G mutation. The m.4435A>G mutation might affect the secondary structure and folding free energy of mitochondrial tRNA and change its stability, which may influence the anticodon ring structure. Compared with the control group, the cell lines carrying m.4435A>G and YARS2 p.G191V mutations had decreased mitochondrial tRNA homeostasis, mitochondrial protein expression, ATP production and MMP levels, as well as increased ROS levels (all P<0.05).
CONCLUSIONS: The YARS2 p.G191V mutation aggravates the changes in mitochondrial translation and mitochondrial function caused by m.4435A>G through affecting the steady-state level of mitochondrial tRNA and further leads to cell dysfunction, indicating that YARS2 p.G191V and m.4435A>G mutations have a synergistic effect in this family and jointly participate in the occurrence and development of essential hypertension.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences - 53(2024), 2 vom: 25. Apr., Seite 184-193 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
携带线粒体tRNAMet 4435A>G和核基因YARS2突变的原发性高血压家系遗传学分析 |
|---|
| Beteiligte Personen: |
Guo, Meili [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.04.2024 Date Revised 28.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3724/zdxbyxb-2023-0571 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370515331 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370515331 | ||
| 003 | DE-627 | ||
| 005 | 20240429232123.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240403s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3724/zdxbyxb-2023-0571 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1392.xml |
| 035 | |a (DE-627)NLM370515331 | ||
| 035 | |a (NLM)38562030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guo, Meili |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical and genetic analysis of essential hypertension with mitochondrial tRNAMet 4435A>G and YARS2 mutation |
| 246 | 3 | 3 | |a 携带线粒体tRNAMet 4435A>G和核基因YARS2突变的原发性高血压家系遗传学分析 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2024 | ||
| 500 | |a Date Revised 28.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: To investigate the role of m.4435A>G and YARS2 c.572G>T (p.G191V) mutations in the development of essential hypertension | ||
| 520 | |a METHODS: A hypertensive patient with m.4435A>G and YARS2 p.G191V mutations was identified from previously collected mitochondrial genome and exon sequencing data. Clinical data were collected, and a molecular genetic study was conducted in the proband and his family members. Peripheral venous blood was collected, and immortalized lymphocyte lines constructed. The mitochondrial transfer RNA (tRNA), mitochondrial protein, adenosine triphosphate (ATP), mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) in the constructed lymphocyte cell lines were measured | ||
| 520 | |a RESULTS: Mitochondrial genome sequencing showed that all maternal members carried a highly conserved m.4435A>G mutation. The m.4435A>G mutation might affect the secondary structure and folding free energy of mitochondrial tRNA and change its stability, which may influence the anticodon ring structure. Compared with the control group, the cell lines carrying m.4435A>G and YARS2 p.G191V mutations had decreased mitochondrial tRNA homeostasis, mitochondrial protein expression, ATP production and MMP levels, as well as increased ROS levels (all P<0.05) | ||
| 520 | |a CONCLUSIONS: The YARS2 p.G191V mutation aggravates the changes in mitochondrial translation and mitochondrial function caused by m.4435A>G through affecting the steady-state level of mitochondrial tRNA and further leads to cell dysfunction, indicating that YARS2 p.G191V and m.4435A>G mutations have a synergistic effect in this family and jointly participate in the occurrence and development of essential hypertension | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Essential hypertension | |
| 650 | 4 | |a Gene mutation | |
| 650 | 4 | |a Maternal inheritance | |
| 650 | 4 | |a Mitochondrial DNA | |
| 650 | 4 | |a Mitochondrial dysfunction | |
| 650 | 4 | |a Respiratory chain | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a RNA, Transfer |2 NLM | |
| 650 | 7 | |a 9014-25-9 |2 NLM | |
| 650 | 7 | |a RNA, Transfer, Met |2 NLM | |
| 700 | 1 | |a He, Yunfan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Ade |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Zaishou |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Xiaoyong |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Minxin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences |d 2002 |g 53(2024), 2 vom: 25. Apr., Seite 184-193 |w (DE-627)NLM123207037 |x 1008-9292 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2024 |g number:2 |g day:25 |g month:04 |g pages:184-193 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3724/zdxbyxb-2023-0571 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2024 |e 2 |b 25 |c 04 |h 184-193 | ||